AfterQuery | $30,000,000 | (Apr 10, 2026)
Plume (YC S24) | $3,900,000 | (Apr 10, 2026)
Rork | $15,000,000 | (Apr 10, 2026)
Certified by Founder
Lodge
Star Therapeutics
start up
United States
- South San Francisco, California
- 05/09/2023
- Series C
- $90,000,000
Star Therapeutics is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Our innovation engine starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy.
Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within our portfolio to be unveiled, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
- Industry Biotechnology Research
- Website https://star-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/star-tx/about/
Haast | $12,000,000 | (Apr 10, 2026)
CareGlance Srl | $4,092,182 | (Apr 10, 2026)
Elorian AI | $55,000,000 | (Apr 10, 2026)
TeiaCare & Ancelia: AI for Care Homes | $8,184,645 | (Apr 10, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)
Felix(1) | $1,700,000 | (Apr 10, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
Golden Analytics | $7,000,000 | (Apr 9, 2026)